Skip to content
Cefditoren pivoxil
Spectracef (cefditoren pivoxil) is a small molecule pharmaceutical. Cefditoren pivoxil was first approved as Spectracef on 2001-08-29. It is used to treat bacterial infections, bacterial pneumonia, bronchitis, haemophilus infections, and klebsiella infections amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
stomatognathic diseasesD009057
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cefditoren pivoxil
Tradename
Company
Number
Date
Products
SPECTRACEFVansen PharmaN-021222 DISCN2001-08-29
2 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
spectracefNew Drug Application2013-06-04
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bacterial infections—D001424A49
bacterial pneumoniaEFO_1001272D018410J15.9
bronchitis—D001991J40
haemophilus infectionsEFO_1001127D006192—
klebsiella infectionsEFO_1001353D007710—
moraxellaceae infectionsEFO_1001072D045828—
pharyngitis—D010612R07.0
soft tissue infections—D018461—
staphylococcal skin infectionsEFO_1001849D013207L00
streptococcal infectionsEFO_1001476D013290—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01D: Other beta-lactam antibacterials in atc
— J01DD: Third-generation cephalosporins
— J01DD16: Cefditoren
HCPCS
No data
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—8——3—11
Pituitary neoplasmsD010911———1—1
Chronic bronchitisD029481J42———1—1
PneumoniaD011014EFO_0003106J18———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MastitisD008413EFO_1001034N61—11——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Protein-energy malnutritionD011502EFO_0009563E41————11
KwashiorkorD007732EFO_1001009E40————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCEFDITOREN PIVOXIL
INNcefditoren
Description
Cefditoren is a broad spectrum, third-generation cephalosporin antibiotic with (Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. Generally administered as its orally absorbed pivaloyloxymethyl ester prodrug, it is used for the treatment of mild to moderate infections caused by susceptible strains of microorganisms in acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, and uncomplicated skin and skin-structure infections. It has a role as an antibacterial drug. It is a cephalosporin and a carboxylic acid.
Classification
Small molecule
Drug classcephalosporins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(/C=C\c3scnc3C)CS[C@H]12)c1csc(N)n1
Identifiers
PDB—
CAS-ID104145-95-1
RxCUI83682
ChEMBL IDCHEMBL454446
ChEBI ID560555
PubChem CID9870843
DrugBankDB01066
UNII ID81QS09V3YW (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 591 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,500 adverse events reported
View more details